CN103370060A - 治疗癌症/抑制转移 - Google Patents

治疗癌症/抑制转移 Download PDF

Info

Publication number
CN103370060A
CN103370060A CN2010800703488A CN201080070348A CN103370060A CN 103370060 A CN103370060 A CN 103370060A CN 2010800703488 A CN2010800703488 A CN 2010800703488A CN 201080070348 A CN201080070348 A CN 201080070348A CN 103370060 A CN103370060 A CN 103370060A
Authority
CN
China
Prior art keywords
cells
ranolazine
cancer
cell
riluzole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800703488A
Other languages
English (en)
Chinese (zh)
Inventor
穆斯塔法·比尔金·阿里·贾姆戈兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110087549.9A priority Critical patent/CN112755029A/zh
Publication of CN103370060A publication Critical patent/CN103370060A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2010800703488A 2010-10-13 2010-10-13 治疗癌症/抑制转移 Pending CN103370060A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110087549.9A CN112755029A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2010/001908 WO2012049440A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110087549.9A Division CN112755029A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Publications (1)

Publication Number Publication Date
CN103370060A true CN103370060A (zh) 2013-10-23

Family

ID=44022817

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800703488A Pending CN103370060A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移
CN202110087549.9A Pending CN112755029A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110087549.9A Pending CN112755029A (zh) 2010-10-13 2010-10-13 治疗癌症/抑制转移

Country Status (13)

Country Link
US (5) US20130203764A1 (enExample)
EP (4) EP2627321A1 (enExample)
JP (1) JP2013539778A (enExample)
KR (1) KR20140032346A (enExample)
CN (2) CN103370060A (enExample)
AU (2) AU2010362412A1 (enExample)
BR (1) BR112013009086A2 (enExample)
CA (1) CA2851694C (enExample)
DK (1) DK3132791T3 (enExample)
IL (1) IL225689A0 (enExample)
RU (1) RU2013121744A (enExample)
SG (1) SG189352A1 (enExample)
WO (1) WO2012049440A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110662545A (zh) * 2017-02-10 2020-01-07 赛立斯肿瘤学创新有限公司 癌症治疗和转移抑制
CN115350263A (zh) * 2016-05-20 2022-11-18 拜尔哈文制药股份有限公司 谷氨酸调节剂与免疫疗法用以治疗癌症的用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013121744A (ru) 2010-10-13 2014-11-20 Мустафа Билгин Али ДЖАМГОЗ Лечение рака/ингибирование метастазирования
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
WO2017091574A1 (en) * 2015-11-25 2017-06-01 Health Research, Inc. Riluzole and riluzole drug combinations for the treatment of prostate cancer
JP6465306B2 (ja) * 2016-02-04 2019-02-06 セレックス・オンコロジー・リミテッド 癌の治療／転移の阻害
US20200123544A1 (en) * 2018-10-22 2020-04-23 Celex Oncology Innovations Limited Gene therapy targeting the neonatal form of nav1.5 for treating cancer
WO2021078987A1 (en) 2019-10-24 2021-04-29 Celex Oncology Innovations Limited Combination treatments for cancer
US12624101B2 (en) 2020-01-21 2026-05-12 Celex Oncology Innovations Limited Monoclonal antibodies against neonatal Nav1.5
US20230139204A1 (en) 2020-03-09 2023-05-04 Celex Oncology Innovations Limited Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells
WO2022005228A1 (ko) * 2020-07-01 2022-01-06 국립암센터 3-케토아실 coa 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2025078664A1 (en) 2023-10-12 2025-04-17 Celex Oncology Innovations Limited Treatment of metastatic or invasive brain cancer
WO2025252860A1 (en) 2024-06-04 2025-12-11 Celex Oncology Innovations Limited Ranolazine enantiomer for use in cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221246A1 (en) * 2004-04-16 2010-09-02 University Of Medicine And Dentistry Of New Jersey Methods and compositions for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659136A (zh) * 2002-04-18 2005-08-24 弗吉尼亚大学专利基金会 新的钠通道阻滞剂
CA2513399A1 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US9018222B2 (en) 2006-03-27 2015-04-28 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US8394377B2 (en) * 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20110251144A1 (en) * 2008-09-16 2011-10-13 Massachusetts Institute Of Technology Molecular modulators of the wnt/beta-catenin pathway
RU2013121744A (ru) 2010-10-13 2014-11-20 Мустафа Билгин Али ДЖАМГОЗ Лечение рака/ингибирование метастазирования

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221246A1 (en) * 2004-04-16 2010-09-02 University Of Medicine And Dentistry Of New Jersey Methods and compositions for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GING KUO WANG ET AL: "State-and Use-Dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-Gated Na+ Channel Isoforms by Ranolazine", 《MOL PHARMACOL》, vol. 73, no. 3, 31 December 2008 (2008-12-31), pages 940 - 948, XP002589408 *
JKJ DISS ET AL: "β-Subunits of voltage-gated sodium channels in human prostate cancer: quantitative in vitro and in vivo analyses of mRNA expression", 《PROSTATE CANCER AND PROSTATIC DISEASES》, vol. 11, 25 September 2007 (2007-09-25), pages 325 - 333, XP008102099, DOI: doi:10.1038/SJ.PCAN.4501012 *
SCOTT P. FRASER ET AL: "Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis", 《CLINICAL CANCER RESEARCH》, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5381 - 5389, XP002415107, DOI: doi:10.1158/1078-0432.CCR-05-0327 *
YA-JEAN WANG ET AL: "Riluzole-induced block of voltage-gated Na+ current and activation of BKCa channels in cultured differentiated human skeletal muscle cells", 《LIFE SCIENCES》, vol. 82, 31 December 2008 (2008-12-31), pages 11 - 20, XP022392092, DOI: doi:10.1016/j.lfs.2007.10.015 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115350263A (zh) * 2016-05-20 2022-11-18 拜尔哈文制药股份有限公司 谷氨酸调节剂与免疫疗法用以治疗癌症的用途
CN110662545A (zh) * 2017-02-10 2020-01-07 赛立斯肿瘤学创新有限公司 癌症治疗和转移抑制

Also Published As

Publication number Publication date
US20230202994A1 (en) 2023-06-29
AU2010362412A1 (en) 2013-05-30
US11634398B2 (en) 2023-04-25
BR112013009086A2 (pt) 2016-07-26
EP4640281A2 (en) 2025-10-29
EP3132791B1 (en) 2019-11-27
WO2012049440A1 (en) 2012-04-19
EP4640281A3 (en) 2026-01-07
AU2017202267B2 (en) 2019-01-24
US20160096812A1 (en) 2016-04-07
DK3132791T3 (da) 2020-03-09
RU2013121744A (ru) 2014-11-20
KR20140032346A (ko) 2014-03-14
IL225689A0 (en) 2013-06-27
CN112755029A (zh) 2021-05-07
US20130203764A1 (en) 2013-08-08
CA2851694C (en) 2019-02-26
EP3653206A1 (en) 2020-05-20
US12534444B2 (en) 2026-01-27
CA2851694A1 (en) 2012-04-19
US20200017457A1 (en) 2020-01-16
EP2627321A1 (en) 2013-08-21
EP3132791A1 (en) 2017-02-22
SG189352A1 (en) 2013-05-31
JP2013539778A (ja) 2013-10-28
US20180346431A1 (en) 2018-12-06
AU2017202267A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
US12534444B2 (en) Treatment of cancer/inhibition of metastasis
Guo et al. 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N′-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A
US12605390B2 (en) Treatment of cancer and inhibition of metastasis
Tsukimoto et al. Anti‐inflammatory potential of remimazolam: A laboratory and clinical investigation
JP2013170168A (ja) 化合物及びその医薬組成物
WO2012049439A1 (en) Treatment of cancer/inhibition of metastasis
JP2019001826A (ja) 癌の治療／転移の阻害
JP2022179708A (ja) 癌の治療／転移の阻害
JP6465306B2 (ja) 癌の治療／転移の阻害
Cui et al. Ketamine inhibits lung fluid clearance through reducing alveolar sodium transport
JP2021516695A (ja) 腫瘍転移の薬物治療における標的、及びその使用
GB2484513A (en) Treatment of cancer/inhibition of metasesis using ranolazine or riluzole
Cruz et al. 118 NGF-INDUCE DETRUSOR OVERACTIVITY IS TRPV1 DEPENDENT
Yokovama et al. 117 EFFECTS OF ENCEPHALIN GENE THERAPY USING HERPES SIMPLEX VIRUS VECTOR ON BLADDER HYPERACTIVITYAND NOCICEPTION
Park et al. 116 ARE CLINICALLY INSIGNIFICANT PROSTATE CANCERS REALLY INSIGNIFICANT IN THE KOREAN POPULATION?

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20131023